Clinical Trial Update: A Study to Evaluate the Safety, Tolerability and PK of SK-09 [Phase 1]

View source ↗

Summary

A Phase 1 study is evaluating the safety, tolerability and pharmacokinetics of SK-09 for focal segmental glomerulosclerosis and minimal change disease, with ong…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Segmental Glomerulosclerosis
• Minimal Change Disease

Drugs mentioned

• SK-09

Snippet

Sponsor: Consun Pharmaceutical Group | Conditions: FSGS, MCD | Phase 1 | Status: RECRUITING